Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo^®)

References

• GelbDJOliverEGilmanSDiagnostic criteria for Parkinson diseaseArch Neurol199956133399923759
   PubMed Web of Science ®Google Scholar
• de LauLMLBretelerMMBEpidemiology of Parkinson’s diseaseLancet Neurol20065652553516713924
   PubMed Web of Science ®Google Scholar
• NussbaumRLEllisCEAlzheimer’s disease and Parkinson’s diseaseN Engl J Med2003348141356136412672864
   PubMed Web of Science ®Google Scholar
• MüllerTLevodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety, and patient preferencePatient Preference and Adherence20093515919936145
   PubMed Web of Science ®Google Scholar
• OlanowCWWattsRLKollerWCAn algorithm (decision tree) for the management of Parkinson diseaseNeurology20015611 Suppl 5S1S8811402154
   PubMed Web of Science ®Google Scholar
• JancovicJStacyMMedical management of levodopa-associated motor complications in patients with Parkinson’s DiseaseCNS Drugs 200721867769217630819
   PubMed Web of Science ®Google Scholar
• MarsdenCDParkesJDSuccess and problems of long-term levodopa therapy in Parkinson’s diseaseLancet19771800734534964868
   PubMed Web of Science ®Google Scholar
• van LaarTLevodopa-induced response fluctuations in patients with Parkinson’s disease: strategies for managementCNS Drugs20031747548912751918
   PubMed Web of Science ®Google Scholar
• HauserRAMcDermottMPMessingSFactors associated with the development of motor fluctuations and dyskinesias in Parkinson DiseaseArch Neurol2006631756176017172616
   PubMed Web of Science ®Google Scholar
• ObesoJARodriguez-OrozMCChanaPLeraGRodriguezMOlanowCWThe evolution and origin of motor complications in Parkinson’s diseaseNeurology200055Suppl 4S13S20 discussion S21–S2311147505
   PubMed Web of Science ®Google Scholar
• ObesoJARodriguez-OrozMMarinCThe origin of motor fluctuations in Parkinson’s disease: importance of dopaminergic innervation and basal ganglia circuitsNeurology200462Suppl 1S17S3014718677
   PubMed Web of Science ®Google Scholar
• OlanowCWMovement disorders: a step in the right directionLancet Neurol200653516361007
   PubMed Web of Science ®Google Scholar
• DeweyRBJrManagement of motor complications in Parkinson’s diseaseNeurology200462Suppl 4S3S715037664
   PubMed Web of Science ®Google Scholar
• RiedererPGerlachMMüllerTReichmannHRelating mode of action to clinical practice: dopaminergic agents in Parkinson’s diseaseParkinsonism Relat Disord200713846647917919963
   PubMed Web of Science ®Google Scholar
• JankovicJParkinson’s disease therapy: tailoring choices for early and late disease, young and old patientsClin Neuropharmacol20002325226111154092
   PubMed Web of Science ®Google Scholar
• BergamascoBFrattolaLMuratorioAPiccoliFMaillandFParnettiLAlpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled studyActa Neurol Scand200010137238010877152
   PubMed Web of Science ®Google Scholar
• BaronePBraviDBermejo-ParejaFfor Pergolide Monotherapy Study GroupPergolide monotherapy in the treatment of early PD: a randomized, controlled studyNeurology19995357357910449123
   PubMed Web of Science ®Google Scholar
• ShannonKMBennettJPJrFriedmanJHfor Pramipexole Study GroupEfficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson‘s diseaseNeurology1997497247289305331
   PubMed Web of Science ®Google Scholar
• AdlerCHSethiDKHauserRARopinirole for the treatment of early Parkinson’s diseaseNeurology1997493933999270567
   PubMed Web of Science ®Google Scholar
• GiladiNBoroojerdiBKorczynADBurnDJClarkeCESchapiraAHSP513 investigatorsRotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropiniroleMov Disord200722162398240417935234
   PubMed Web of Science ®Google Scholar
• JankovicJAguilarLGCurrent approaches to the treatment of Parkinson’s diseaseNeuropsychiatr Dis Treat2008474375719043519
   PubMedGoogle Scholar
• OertelWHWoltersESampaioCPergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET studyMov Disord20052134335316211594
   PubMed Web of Science ®Google Scholar
• BraccoFBattagliaAChouzaCThe long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled studyCNS Drugs20041873374615330687
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupPramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trialJAMA20002841931193811035889
   PubMed Web of Science ®Google Scholar
• HollowayRGShoulsonIFahnSPramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialArch Neurol2004611044105315262734
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJKorczynADDe DeynPPClarkeCELangAEfor 056 Study GroupA five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopaN Engl J Med20003421484149110816186
   PubMed Web of Science ®Google Scholar
• WhoneALRemyPDavisMRThe REAL-PET study: slower progression in early Parkinson’s disease treated with ropinirole compared with levodopaNeurology200258Suppl 3A82A83
   Google Scholar
• Parkinson Study GroupDopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progressionJAMA20022871653166111926889
   PubMed Web of Science ®Google Scholar
• VoonVPessiglioneMBrezingCMechanisms underlying dopamine-mediated reward bias in compulsive behaviorsNeuron201065113514220152119
   PubMed Web of Science ®Google Scholar
• ZanettiniRAntoniniAGattoGGentileRTeseiSPezzoliGValvular heart disease and the use of dopamine agonists for Parkinson’s diseaseN Engl J Med 20073561394617202454
   PubMed Web of Science ®Google Scholar
• LugingerEWenningGKBoschSPoeweWBeneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s diseaseMov Disord200015587387811009193
   PubMed Web of Science ®Google Scholar
• SnowBJMacdonaldLMcauleyDWallisWThe effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled studyClin Neuropharmacol2000232828510803797
   PubMed Web of Science ®Google Scholar
• HenchcliffeCSchumacherHCBurgutFTRecent advances in Parkinson’s disease therapy: use of monoamine oxidase inhibitorsExpert Rev Neurother 20055681182116274338
   PubMedGoogle Scholar
• PalhagenSHeinonenEHagglundJSelegiline slows the progression of the symptoms of Parkinson diseaseNeurology2006661200120616540603
   PubMed Web of Science ®Google Scholar
• OlanowCWRascolOHauserRADAGIO Study InvestigatorsA double-blind, delayed-start trial of rasagiline in Parkinson’s diseaseN Engl J Med2009361131268127819776408
   PubMed Web of Science ®Google Scholar
• StocchiFThe levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerationsExpert Opin Pharmacother200671399140716805724
   PubMedGoogle Scholar
• PahwaRBusenbarkKHuberSJMichalekDHubbleJPKollerWCClinical experience with controlled-release carbidopa/levodopa in Parkinson’s diseaseNeurology1993436776818469321
   PubMed Web of Science ®Google Scholar
• KollerWCPahwaRTreating motor fluctuations with controlled- release levodopa preparationsNeurology199444Suppl 6S23S288047257
   PubMed Web of Science ®Google Scholar
• KollerWCHuttonJTTolosaECapilldeoRImmediate-release and controlled-release carbidopa/levodopa in PD: a five year randomized multicenter study. Carbidopa/Levodopa Study GroupNeurology19995351012101910496260
   PubMed Web of Science ®Google Scholar
• GuldbergHCMarsdenCACatechol-O-methyl transferase: pharmacological aspects and physiological rolePharmacol Rev1975271352061103160
   PubMed Web of Science ®Google Scholar
• KaakkolaSClinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s diseaseDrugs20005961233125010882160
   PubMed Web of Science ®Google Scholar
• MüllerTTolcapone in the management of Parkinson’s diseaseAging Health200625709720
   Google Scholar
• RuottinenHMRinneUKCOMT inhibition in the treatment of Parkinson’s diseaseJ Neurol199824511 Suppl 32534
   Web of Science ®Google Scholar
• SchragAEntacapone in the treatment of Parkinson’s diseaseLancet Neurol2005436637015907741
   PubMed Web of Science ®Google Scholar
• LeesAJRatziuVTolosaEOertelWHSafety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s diseaseJ Neurol Neurosurg Psichiatry2007789944948
   Web of Science ®Google Scholar
• RuottinenHMRinneUKA double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s diseaseClin Neuropharmacol1996192832968828991
   PubMed Web of Science ®Google Scholar
• HeikkinenHVarheALylyVNew levodopa. carbidopa and entcapone combination tabletsEuropean J Neurology 200310164
   Google Scholar
• HauserRALevodopa/carbidopa/entacapone (Stalevo)Neurology2004626471
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupEntacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patientsAnn Neurol1997427477559392574
   PubMed Web of Science ®Google Scholar
• RinneUKLarsenJPSidenAWorm-PetersonJEntacapone enhances the response to levodopa in parkinsonian patients with motor fluctuationsNeurology199851186189
   Web of Science ®Google Scholar
• LarsenJPWorm-PetersenJSidenAGordinAReinikainenKLeinonenMThe tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s diseaseEur J Neurol20031013714612603288
   PubMed Web of Science ®Google Scholar
• FenelonGGimenez-RoldanSMontastrucJLEfficacy and tolerability of entacapone in patients with Parkinson’s disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations: a randomized, double-blind, multicentre studyJ Neural Transm200311023925112658373
   PubMed Web of Science ®Google Scholar
• PicciniPBrooksDJKorpelaKPaveseNKarlssonMGordinAThe catechol-O-methyltransferase (catechol-O-methyltransferase) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s diseaseJ Neurol Neurosurg Psychiatry20006858959410766888
   PubMed Web of Science ®Google Scholar
• DurifFDevauxIPereJJDelumeauJCBourdeixIEfficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and end-of-dose deterioration in daily medical practice: an open, multicenter studyEur Neurol20014511111811244274
   PubMed Web of Science ®Google Scholar
• OnofrjMThomasAVingerhoetsFCombining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label studyJ Neural Transm 200411181053106315254793
   PubMed Web of Science ®Google Scholar
• ReichmannHBoasJMacmahonDMyllylaVHakalaAReinikainenKEfficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuationsActa Neurol Scand2005111212815595934
   PubMed Web of Science ®Google Scholar
• PoeweWHDeuschlGGordinAKultalahtiERLeinonenMEfficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled doubleblind study in Germany and Austria (Celomen study)Acta Neurol Scand200210524525511939936
   PubMed Web of Science ®Google Scholar
• BrooksDJSagarHEntacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month studyJ Neurol Neurosurg Psychiatry2003741071107912876237
   PubMed Web of Science ®Google Scholar
• OlanowCWKieburtzKSternMDouble-blind, placebocontrolled study of entacapone in levodopa-treated patients with stable Parkinson diseaseArch Neurol2004611563156815477510
   PubMed Web of Science ®Google Scholar
• BrooksDJAgidYEggertKWidnerHOstergaardKHolopainenATC-INIT Study GroupTreatment of end-of-dose wearing-off in parkinson’s disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatmentEur Neurol200553419720215970632
   PubMed Web of Science ®Google Scholar
• MyllyläVHaapaniemiTKaakkolaSPatient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study)Acta Neurol Scand2006114318118616911346
   PubMed Web of Science ®Google Scholar
• EggertKSkogarOAmarKDirect switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility – an open-label, 6-week studyJ Neural Transm2010117333334220013007
   PubMed Web of Science ®Google Scholar
• HauserRAPanissetMAbbruzzeseGMancioneLDronamrajuNKakariekaAFIRST-STEP Study GroupDouble-blind trial of levodopa/ carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s diseaseMov Disord200924454155019058133
   PubMed Web of Science ®Google Scholar
• MüllerTMuhlackSPeripheral COMT inhibition prevents levodopa associated homocysteine increaseJ Neural Transm2009116101253125619657587
   PubMed Web of Science ®Google Scholar
• MarinCAguilarEBonastreMTolosaEObesoJAEarly administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian ratsExp Neuro2005192184193
   Web of Science ®Google Scholar
• HadjTAGregoireLBangassoroEBedardPJSustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeysClin Neuropharmacol20002319520211020123
   PubMed Web of Science ®Google Scholar
• OlanowWSchapiraAHRascolOContinuous dopamine-receptor stimulation in early Parkinson’s diseaseTrends Neurosci200023S117S12611052229
   PubMed Web of Science ®Google Scholar
• JennerPAvoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulationNeurolog200462S47S55
   PubMed Web of Science ®Google Scholar
• PearceRKBanerjiTJennerPMarsdenCDDe novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmosetMov Disord1998132342419539335
   PubMed Web of Science ®Google Scholar
• MaratosECJacksonMJPearceRKJennerPAntiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)Mov Disord20011663164111481686
   PubMed Web of Science ®Google Scholar
• KollerWCHuttonJTTolosaECapilldeoRImmediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study GroupNeurology1999531012101910496260
   PubMed Web of Science ®Google Scholar
• NissinenHKuoppamäMLeinonenMSchapiraAHEarly versus delayed initiation of entacapone in levodopa-treated patients with Parkinson_s disease: a long-term, retrospective analysisEur J Neurol2009161305131119570145
   PubMed Web of Science ®Google Scholar
• KlivenyPVecseiLNovel therapeutic strategies in Parkinson’s diseaseEur J Clin Pharmacol20106611912519834698
   PubMed Web of Science ®Google Scholar
• MüllerTRole of homocysteine in the treatment of Parkinson’s diseaseExpert Rev Neurother20088695796718505360
   PubMedGoogle Scholar
• Ben ShlomoYMarmotMGSurvival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?J Neurol Neurosurg Psychiatry19955832932997897409
   PubMed Web of Science ®Google Scholar
• GorellJMJohnsonCCRybickiBAParkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990Neurology19944410186518687936238
   PubMed Web of Science ®Google Scholar
• PostumaRBEspayAJZadikoffCVitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled studyNeurology200666121941194316801668
   PubMed Web of Science ®Google Scholar
• NevrlyMKanovskyPVranovaHLangovaKHlustikPEffect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson’s disease patientsParkinsonism Relat Disord200915647747819028438
   PubMed Web of Science ®Google Scholar
• de BonisMLTessitoreAPellecchiaMTImpaired transmethylation potential in Parkinson’s disease patients treated with L-dopaNeurosci Lett2010468328729119909787
   PubMed Web of Science ®Google Scholar
• ValkovicPBenetinJBlazacekPValkovicovaLGmitterovaKKukumbergPReduced plasma homocysteine levels in levodopa/ entacapone treated Parkinson patientsParkinsonism Relat Disord20051125325615878587
   PubMed Web of Science ®Google Scholar
• ZoccolellaSLambertiPArmeniseEPlasma homocysteine levels in Parkinson’s disease: role of antiparkinsonian medicationsParkinsonism Relat Disord20051113113315734674
   PubMed Web of Science ®Google Scholar